Home › NCT07212803
Effects of Energy Drinks on Cardiovascular Endpoints
RecruitingPhase 4Healthy volunteers welcome
Evaluation of Energy Drinks on Electrocardiographic Parameters: A Randomized, Double Blind, Controlled, Crossover, Proof-of-concept Study
Who can join
Ages 18 to 40 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Healthy male or female adults 18-40 years of age * Female participants of child-bearing potential must have a negative pregnancy test at the baseline visit * Participants must be willing to refrain from caffeine and alcohol use 72 hours prior to sessions on study days * Participants must be willing and able to: (1.) Consume up to 1 liter of fluid within a 30-minute period per visit (2.) Swallow a single large capsule per visit * Participants must be willing to fast 10 hours prior to sessions on study days (only water is allowed during the fasting and active study period) * Participants must have active health insurance throughout the duration of the study Exclusion Criteria: * Have a corrected QT (QTc) interval greater than 450 milliseconds (ms) for males or greater than 470 milliseconds (ms) for females, determined during the baseline visit * Presence of any known medical condition, confirmed through participant interview. Examples of these include but not limited to: Dyslipidemia, Thyroid disease, Diabetes, Recurrent headache, Any psychiatric condition or neurological disorder, History of alcohol or drug abuse, Past diagnosis or history of renal insufficiencies, Hepatic dysfunction, Electrolyte imbalances requiring hospitalization * Presence of any known heart/cardiac diseases or conditions such as: Atrial Fibrillation, History of stroke or heart attack, Hypertension, Heart Failure, Vascular Disease, Family history/Active Long QT Syndrome, Coronary artery disease, Cardiomyopathy, Valvular heart disease, Ventricular arrhythmia, Congenital heart defect, Pericardial disease, Myocarditis * Study physician recommendation for participant to not be enrolled. * Are underweight (BMI\<18.5 kg/m2, CDC 2024), have poor eating habits resulting in poor weight control, or have any factors that will put the participant at risk from fasting. * Have any contraindications to the use of moxifloxacin, including a past medical history of myasthenia gravis, QT prolongation, or hypersensitivities and allergic reactions to moxifloxacin or any other fluoroquinolone antibiotics * Pre-existing risk to tendinitis and tendon rupture, peripheral neuropathy, or central nervous system side effects * Concurrent use of ANY medication taken daily including herbal products or supplements (daily basis is defined as greater than 2 days per week) * Self-reported allergy to taurine * Self-reported allergy to nuts (peanuts, pecans, cashews, etc.) * Self-reported allergic reaction to the adhesive pads (electrodes, continuous glucose monitors, etc.) * Fear of needle puncture * Smokers using cigarettes, vaporized nicotine, or marijuana products currently or within the past month * Current usage of any nicotine or tobacco products including but not limited to intranasal, sublingual, oral, or transdermal dosage forms * Currently pregnant or breastfeeding * Have a positive pregnancy test during the baseline visit * Are currently enrolled in any other clinical study or have participated in another study within the last 30 days * Non-English speaking/reading individuals will be excluded due to the unavailability of medically qualified translators throughout all study procedures * If the candidate does not sign the informed consent document
About the study
This is a clinical trial looking at the impact of energy drinks on heart related parameters. The study will enroll 3 participants who will be exposed to 8 different interventions.
What is being tested
- Energy Drink A + Placebo Capsule (dietary supplement)
- Placebo Drink + Moxifloxacin Capsule (drug)
- Placebo Drink + Caffeine Capsule (dietary supplement)
- Placebo Drink + Placebo Capsule (other)
- Energy Drink B (dietary supplement)
- Control Product + Taurine (dietary supplement)
Sponsor: University of the Pacific · Participants: 3 · Started: Nov 1, 2025
Contact the study team
- Quy Phan, PharmD · Phone: 209-946-7754
Official record on ClinicalTrials.gov — NCT07212803
Locations in the U.S.
| California | University of the Pacific, Stockton |
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.